Business By Matthew Herper Merck to spin off new $6.5 billion firm focused on women’s health, older drugs
First Opinion By Hillel P. Cohen and Dorothy McCabe Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions
Pharmalot By Ed Silverman Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins
Politics By Lev Facher Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation
First Opinion By Jessica Sagers and Peter Kolchinsky Booker-Sanders-Harris drug affordability bureau could be brilliant
Pharmalot By Ed Silverman Biosimilars got the cold shoulder from health plans when it came to preferred coverage
Pharmalot By Ed Silverman Large employers could have saved money if more biosimilars had been prescribed
Pharmalot By Ed Silverman FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake
Pharmalot By Ed Silverman Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals
Pharmalot By Ed Silverman Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast
Pharmalot By Ed Silverman Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill
First Opinion By Jonathan Kimball Trade agreement drug monopoly is obsolete given faster, better drug discovery
Pharmalot By Ed Silverman Pharmalittle: New records show drug makers’ opioid push; Senate bill would cap Medicare drug price hikes
Pharmalot By Ed Silverman Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin
Pharmalot By Ed Silverman Pharmalittle: Democrats eye negotiating for all drug plans; feds want part of Oklahoma settlement with Purdue
Pharmalot By Ed Silverman FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed
Pharmalot By Ed Silverman AbbVie settles key patent litigation over Humira, preserving ‘monopoly prices’ in the U.S.
Pharmalot By Ed Silverman AbbVie is eager for its new psoriasis drug to be a hit, but analysts offer caveats
Pharmalot By Ed Silverman Pharmalittle: U.K. adviser complains pharma ignores antibiotics; FDA to revamp manufacturing rules
First Opinion By Carlos Sattler and Sheila Frame Biosimilar approval and adoption in the U.S. needs to be expedited
Pharmalot By Ed Silverman What’s in a name? FDA changes course for biosimilar names and upsets generic makers
Pharmalot By Ed Silverman AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument
Pharmalot By Ed Silverman Pharmalittle: Senate committee ‘reinvites’ big drug makers to testify; can pharma use AI to solidify patents?
First Opinion By Richard Markus Biosimilars and interchangeability: The FDA’s science-based standards will ensure safety
Pharmalot By Ed Silverman Pharmalittle: Glaxo looks for a new chairman; FDA ponders whom to furlough as shutdown drags on
Pharmalot By Ed Silverman Pharmalittle: A new year brings rising drug prices; Democratic presidential contenders target drug prices